The updated guideline on dyslipidaemia is in concordance with European guidelines (2016). Management of dyslipidaemia aims to reduce the risk of vascular atherosclerotic diseases. Therapeutic targets for plasma LDL cholesterol, determined by risk assessment, range from concentrations < 1.8 mmol/l (persons at very high risk) and < 2.5 mmol/l (high risk) to < 3.0 mmol/l (moderate or low risk). Changes in lifestyle (diet, including replacement of saturated with unsaturated fat, and weight loss; physical activity, and nonsmoking) are the cornerstones, to be continued also with drug therapy. Drugs, mainly statins, are initiated when risk-stratified LDL targets are not reached otherwise.
Timo Strandberg (Chair)
Matti K. Salo